You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3 gene mutation

Showing 1 - 25 of 9,003
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Recruiting
  • Bladder Cancer
  • +12 more
  • Raleigh, North Carolina
    xCures Virtual Site
Sep 20, 2021

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 25, 2022

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with

Recruiting
  • Metastatic Solid Tumor
  • +4 more
  • Recommendation for treatment with immunotherapy
  • Baltimore, Maryland
    Johns Hopkins University
Sep 8, 2022

FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid

Not yet recruiting
  • Acute Myeloid Leukemia
    • (no location specified)
    May 17, 2022

    Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation, Vascular Malformations Trial in Parkville (Alpelisib,

    Not yet recruiting
    • Slow-Flow Vascular Malformation
    • +17 more
    • Parkville, Victoria, Australia
      The Royal Children's Hospital
    Aug 7, 2023

    Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

    Recruiting
    • Advanced Malignant Solid Neoplasm
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 15, 2022

    Bile Acids in Acute Insulin Resistance

    Recruiting
    • PI3K Gene Mutation
    • +4 more
    • Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
    • New York, New York
      Columbia University Medical Center
    Oct 6, 2022

    Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma Trial in Worldwide (derazantinib)

    Recruiting
    • Intrahepatic Cholangiocarcinoma
    • Combined Hepatocellular and Cholangiocarcinoma
    • Phoenix, Arizona
    • +40 more
    Mar 7, 2022

    Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

    Not yet recruiting
    • Recurrent Glioblastoma, IDH-Wildtype
    • +2 more
    • Biospecimen Collection
    • +2 more
    • (no location specified)
    May 13, 2023

    Advanced Cholangiocarcinoma, FGFR2 Gene Mutation Trial in Worldwide (BGJ398, Gemcitabine, Cisplatin)

    Active, not recruiting
    • Advanced Cholangiocarcinoma
    • FGFR2 Gene Mutation
    • Gilbert, Arizona
    • +115 more
    Oct 17, 2022

    Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

    Completed
    • Metastatic Breast Cancer
    • +2 more
    • Control group
    • Case group
    • (no location specified)
    Jun 16, 2022

    People Who Have Genetic Changes and Features of Autism: Simons

    Recruiting
    • 16P11.2 Deletion Syndrome
    • +184 more
      • New York, New York
      • +1 more
      Jan 6, 2023

      Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

      Recruiting
      • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
      • +2 more
      • Futibatinib and Binimetinib
      • Santa Monica, California
      • +2 more
      Jun 2, 2022

      NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

      Not yet recruiting
      • Non-Small Cell Lung Cancer
      • Telisotuzumab Vedotin
      • +4 more
      • (no location specified)
      Oct 17, 2023

      Patogenic Mutation in 5 Genes

      Completed
      • Colorectal Cancer
      • +5 more
      • co-occuring mutation
      • Jakarta, ALL, Indonesia
        Vania Myralda Giamour Marbun
      Jul 21, 2021

      Leber's Hereditary Optic Neuropathy (LHON) Trial in Beijing (NR082 injection, Sham Injection)

      Recruiting
      • Leber's Hereditary Optic Neuropathy (LHON)
      • NR082 injection
      • Sham Injection
      • Beijing, China
        Beijing Tongren Hospital, Capital Medical University
      Dec 21, 2021

      Natural History Study of CADASIL

      Recruiting
      • Cardiovascular Disease
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Oct 29, 2022